Viral hemorrhagic fevers (VHFs) refer to a group of illnesses that are caused by several distinct families of viruses. In general, the term "viral hemorrhagic fever" is used to describe a severe multisystem syndrome (multisystem in that multiple organ systems in the body are affected). Characteristically, the overall vascular system is damaged, and the body's ability to regulate itself is impaired. These symptoms are often accompanied by hemorrhage (bleeding); however, the bleeding is itself rarely life-threatening. While some types of hemorrhagic fever viruses can cause relatively mild illnesses, many of these viruses cause severe, life-threatening disease.
Availability of safe platelets is a fundamental blood transfusion challenge and can be especially problematic in times of emergency. Several studies presented at the annual American Association of Blood Banks (AABB) meeting today demonstrate new approaches to counteract platelet shortages by enhancing the safety of whole blood derived platelets, precluding the need to rely on only those obtained through apheresis.
"Flaviviruses exact an enormous toll in terms of illness and death worldwide," notes NIAID Director Anthony S. Fauci, M.D. "Because this is a relatively new field of study, everything we learn about how these viruses operate is significant.
A monoclonal antibody that can effectively treat mice infected with West Nile virus has an intriguing secret: Contrary to scientists' expectations, it does not block the virus's ability to attach to host cells. Instead, the antibody somehow stops the infectious process at a later point.
A new study of the disease burden of dengue fever in Malaysia strengthens the case for development of a vaccine against the mosquito-borne illness.
Scientists say that a genetically engineered virus may possibly offer the first effective vaccine against Lassa fever.
Among the family of viral hemorrhagic fevers (which includes those caused by the Ebola, Marburg, and Hanta viruses), Lassa fever is the biggest public health problem.
In one of the first molecular studies of the human antibody response to yellow fever, Howard Hughes Medical Institute (HHMI) researchers and their colleagues have found the crucial bit of virus that people's immune systems need to spot and quash this often-fatal re-emerging disease.
Scientists from the Public Health Agency of Canada - with assistance from the U.S. Army Medical Research Institute of Infectious Diseases - have developed vaccines against the Ebola and Marburg viruses that have been shown to be effective in non-human primates.
The World Health Organization (WHO) and health authorities in Angola have confirmed 275 cases including 255 deaths, in an outbreak of Marburg virus in north-western Angola since April 27 this year.
GenoMed announced today that it has launched a free clinical trial to combat the current Marburg virus epidemic in Angola.
Medical teams attempting to control the worst outbreak ever recorded of the deadly Marburg virus in Angola are beginning to see the light at the end of the tunnel as cooperation from stricken communities improves, the U.N. health agency said.
Ebola virus reproduction in laboratory-grown cells is severely hampered by enzyme-inhibiting chemicals, and these chemicals deserve further study as possible treatments for Ebola virus infections in humans, report scientists supported in part by the National Institute of Allergy and Infectious Diseases (NIAID).
Disease experts in Angola say it will be weeks before it is determined whether the on-going Marburg crisis can be averted in Angola where the disease has already killed at least 194 people.
The World Health Organisation (WHO) have sent communications experts into Uige, the epicentre of the outbreak of Marburg epidemic to help Health experts in the fight to contain and eradicate the killer virus. It is hoped they will send a clear message to Angolans to take the necessary measures to fight the virus.
The Marburg virus has already killed 193 people since the outbreak began in northern Angola in October and now South Africa is taking precautions to prevent the spread of the Marburg virus into the country.
Peregrine Pharmaceuticals today announced that there will be two presentations, April 4 and 6, at the American Association of Immunologists (AAI) annual meeting in San Diego, California, indicating the anti-viral potential of its Tarvacin antibody. Dr. Melina Soares of The University of Texas Southwestern Medical Center at Dallas will present pre-clinical data titled "Targeting inside-out phospholipids on viruses in a guinea pig model of Lassa fever."
In an effort to control the Marburg virus outbreak in Angola, Health officials from the Centers for Disease Control and Prevention in Atlanta will assist the World Health Organization by going to Angola to help with outbreak investigation, infection control and laboratory diagnosis of the disease.
Carlos Alberto, a spokesman for the Angolan health ministry, says the death toll in the Marburg hemorrhagic fever outbreak in Angola has now risen to 122, just one fewer than in the largest previous outbreak of the disease, in the Democratic Republic of the Congo from 1998 to 200 and killed 123 of 149 people infected.
The World Health Organization (WHO) announced yesterday that laboratory tests have shown that the cause of a hemorrhagic fever outbreak in northern Angola is the Marburg virus.
More than 90 people have died in Angola from what experts believe to be acute hemorrhagic fever syndrome.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.